New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export NVO’s income statement to Excel — free account
Novo Nordisk A/S
NVOHealthcare Drug Manufacturers General
Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.
- Revenue
- +3.87%
- EPS
- −17.1%
- Free cash flow
- −14.8%
- Total debt
- +30.7%
Quarter to September 2026, against a year earlier
38.51
0.38
−0.98%
Follow NVO
Alert me
Revenue to profit Twelve months to Sep 30, 2026
Of every $100 of revenue, $32.68 was left as profit. What is an income statement?
| Revenue | 51.9 | 100.0% |
|---|---|---|
| Cost of revenue | −9.9 | −19.1% |
| Gross profit | 42.0 | 80.9% |
| Research & development | −9.7 | −18.6% |
| Selling, general & admin | −9.8 | −18.9% |
| Other operating costs | −0.4 | −0.7% |
| Operating income | 22.1 | 42.7% |
| Other income, net | +0.5 | 0.9% |
| Income tax | −4.9 | −9.5% |
| Other items | −0.7 | −1.4% |
| Net income | 17.0 | 32.7% |
Net margin (right axis)
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Revenue | $46.8B | $50.9B | $51.5B | $51.9B |
| Operating income | $19.3B | $23.2B | $22.3B | $22.1B |
| Net income | $15.5B | $19.0B | $17.9B | $17.0B |
| Net margin (right axis) | 33.1% | 37.3% | 34.8% | 32.7% |
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Revenue |
51,914.26 | 51,459.47 | 50,936.69 | 46,792.29 |
+8 more TTM periods Free account |
Cost of Revenue |
9,922.79 | 9,918.05 | 9,211.17 | 8,900.50 | |
Gross Profit |
41,991.49 | 41,541.43 | 41,725.53 | 37,891.78 | |
R&D Expenses |
9,678.85 | 9,024.33 | 8,034.72 | 7,878.71 | |
SG&A Expenses |
9,810.32 | 10,106.90 | 10,436.62 | 10,640.24 | |
Operating Income |
22,148.38 | 22,313.29 | 23,190.19 | 19,327.42 | |
Non-operating Income/Expense |
471.04 | 1,001.26 | 1,084.35 | 436.33 | |
Non-operating Interest Expenses |
736.02 | 322.10 | 842.81 | 1,026.19 | |
| 22,619.42 | 23,314.54 | 24,274.53 | 19,763.76 | ||
Income Tax Provision |
4,923.78 | 5,063.93 | 5,258.70 | 4,255.25 | |
Income after Tax |
17,695.64 | 18,250.62 | 19,015.84 | 15,508.51 | |
Net Income Common |
17,695.64 | 18,250.62 | 19,015.84 | 15,508.51 | |
EPS (Basic) |
3.97 | 4.09 | 4.26 | 3.47 | |
EPS (Diluted) |
3.97 | 4.09 | 4.26 | 3.47 | |
Shares (Basic, Weighted) |
4,431.42 | 4,441.55 | 4,443.45 | 4,442.92 | |
Shares (Diluted, Weighted) |
4,437.37 | 4,444.67 | 4,447.39 | 4,446.64 | |
Gross Margin |
80.89% | 80.73% | 81.92% | 80.98% | |
EBIT Margin |
42.66% | 43.36% | 45.53% | 41.30% | |
EBT margin |
43.57% | 45.31% | 47.66% | 42.24% | |
Net Profit Margin |
34.09% | 35.47% | 37.33% | 33.14% | |
Free Cash Flow Margin |
13.25% | 14.79% | 9.55% | 9.38% | |
EBITDA |
27,249.73 | 26,477.23 | 26,531.59 | 22,655.50 | |
EBIT |
22,148.38 | 22,313.29 | 23,190.19 | 19,327.42 | |
EPS (Diluted, from Cont. Ops) |
3.98 | 4.10 | 4.27 | 3.49 | |
EPS (Diluted, Consolidated) |
3.98 | 4.10 | 4.27 | 3.49 | |
EPS (Basic, Consolidated) |
3.99 | 4.11 | 4.28 | 3.49 | |
Shares (Diluted, Average) |
4,436.16 | 4,443.64 | 4,446.36 | 4,447.33 | |
EPS (Basic, from Continuous Ops) |
3.99 | 4.11 | 4.28 | 3.49 | |
Income from Continuous Operations |
17,695.64 | 18,250.62 | 19,015.84 | 15,508.51 | |
Consolidated Net Income/Loss |
17,695.64 | 18,250.62 | 19,015.84 | 15,508.51 | |
EBITDA Margin |
52.49% | 51.45% | 52.09% | 48.42% | |
Operating Cash Flow Margin |
37.00% | 39.69% | 35.99% | 38.54% |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026